TIGIT/VSTM3/VSIG9 (Immune Checkpoint for Cancer) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-TIGIT/VSTM3/VSIG9 (Immune Checkpoint for Cancer) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | TIGIT/VSTM3/VSIG9 (Immune Checkpoint for Cancer) |
| Clone | [TIGIT/3017] |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG2c, kappa |
| Format | purified |
| Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
| Concentration | n/a |
| Applications | ELISA (EIA), Flow Cytometry (FC/FACS), Immunohistochemistry (IHC) Paraffin |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Specificity: TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4+ T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation). It has been demonstrated to be upregulated on T cells in many cancers and is an immuno-oncology target for t |
| Immunogen | Immunogen: Recombinant fragment (around aa 22-141) of human TIGIT protein (exact sequence is proprietary) |
| Other Names | [T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain containing 9 (VSIG9); V-set and transmembrane domain containing 3 (VSTM3); Washington University cell adhesion molecule (WUCAM)] |
| Gene, Accession # | [TIGIT], Gene ID: 201633, UniProt: Q495A1 |
| Catalog # | MBS4380855 |
| Price | $190, $340, $340 |
| Order / More Info | TIGIT/VSTM3/VSIG9 (Immune Checkpoint for Cancer) Antibody from MYBIOSOURCE INC. |
| Product Specific References | 1. Johnston et al., The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 T Cell Effector Function, Cancer Cell (2014). 2. Dougall WC, et al. TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276: 112-12. |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies